Does Operation Warp Speed Deserve Credit for Pfizer’s Success in Developing a COVID Vaccine?

The pharma giant did not take federal money for research and development, but it did sign an advance purchase agreement.

By Khaya Himmelman

Nov 10, 2020

On Monday, Pfizer announced that in trials, its COVID-19 vaccine candidate was more than 90 percent effective in preventing the disease. Pfizer, which is developing the vaccine in conjunction with German drug company BioNTech, is now, according to a press release from the company: “working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.”

In response to Pfizer’s announcement, Fox News contributor and conservative podcast host Sara Carter tweeted the following:

This is Operation Warp Speed thank you @realDonaldTrump for believing in Science and giving us a future of freedom so America doesn't have to hide behind a mask. 😊Hopefully this is bye bye #ChinaVirus #COVID19 https://t.co/bYQf4ABHEy
— Sara A. Carter (@SaraCarterDC) November 9, 2020

Operation Warp Speed is a federal initiative developed earlier this year with the goal of making and distributing “300 million doses of safe and effective vaccines with the initial doses available by January 2021,” according to the U.S. Department of Health and Human Services.

Join to continue reading

Get started with a free account or join as a member for unlimited access to all of The Dispatch. Continue ALREADY HAVE AN ACCOUNT? SIGN IN